The IND was approved by the Division of Pulmonary, Allergy, and Critical Care at FDA on and Biohaven was informed that the study may proceed immediately.
Vazegepant is currently advancing to Phase 3 development for the acute treatment of migraine in adults under the Division of Neurology, having recently reported a successful end of Phase 2 clinical and nonclinical interaction with FDA.